Polysaccharide conjugated vaccine - Petrovax Pharm
Alternative Names: GNG-DELatest Information Update: 28 Mar 2025
At a glance
- Originator Petrovax Pharm
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Meningococcal infections
Most Recent Events
- 27 Feb 2025 Preclinical trials in Meningococcal infections (Prevention) in Russia (IM)
- 12 Feb 2025 Petrovax Pharm plans a phase III trial for Meningococcal infections (Prevention, In children, In Adolescents, In adults) (IM), in February 2025 (NCT06834100)